Unit:
Κατεύθυνση Χειρουργική ΟγκολογίαLibrary of the School of Health Sciences
Supervisors info:
Δημήτριος Θεοδώρου, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Γ. Τούτουζας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αντώνιος Βεζάκης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Αναδρομική μελέτη του προσδόκιμου πενταετούς επιβίωσης ασθενών με χολαγγειοκαρκίνωμα που υπεβλήθησαν σε ενδοσκοπική παλίνδρομη χολαγγειογραφία με τοποθέτηση μεταλλικής ενδοπρόθεσης
Translated title:
Retrograde study of the survival of patients with cholangiocarcinoma who placed metallic stent by endoscopic retrograde cholangiopancreatography
Summary:
Intoduction. Cholangiocarcinoma is a rare and aggressive malignancy that is usually inoperable during diagnosis. The aim of this study is to evaluate the survival rate of patients after metal stent placement after endoscopic retrograde cholangiopancreatography.
Methods. A retrospective study of 45 patients hospitalized in Hippocration Hospital (2012-2013) and meeting the admission criteria for the study.
Results. The mean age was 70.5 years, with a standard deviation of 14.6 years. The mean survival was 9.3 months. Chemotherapy has a statistically significant contribution to survival (p-value = 0.022), and the chronic hepatic impairment index (MELD) was lower in the chemotherapy group (p-value = 0.022).
There is no statistically significant difference in survival among groups according to the BismuthCorlette classification (p-value = 0.596). . Chemotherapy has statistically significant correlation with bilirubin alone (p-value = 0.009) The lower the bilirubin the higher the survival (p-value = 0.043)
Conclusions. For the optimal care and treatment of patients with cholangiocarcinoma, an interdisciplinary approach is required and in order to achieve progress in therapy, patients should be included in prospective clinical trials to test new approaches.
Main subject category:
Health Sciences
Keywords:
Cholangiocarcinoma, Metallic stent, ERCP, Survival
